At Guangzhou Medical University, an AI model named NeoPred uses dual-phase CT and clinical data to predict lung cancer tumor response preoperatively, potentially refining treatment decisions. Concurrently, ProFound Therapeutics partnered with Novartis in a $25 million deal to leverage AI-driven protein identification for cardiovascular drug targets, indicating rapid expansion in AI applications across oncology and cardiovascular therapeutics.